Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Total Liabilities (2020 - 2025)

Pulse Biosciences has reported Total Liabilities over the past 6 years, most recently at $16.1 million for Q3 2025.

  • Quarterly results put Total Liabilities at $16.1 million for Q3 2025, up 15.49% from a year ago — trailing twelve months through Sep 2025 was $16.1 million (up 15.49% YoY), and the annual figure for FY2024 was $17.6 million, up 18.95%.
  • Total Liabilities for Q3 2025 was $16.1 million at Pulse Biosciences, up from $15.8 million in the prior quarter.
  • Over the last five years, Total Liabilities for PLSE hit a ceiling of $81.4 million in Q3 2022 and a floor of $12.9 million in Q1 2024.
  • Median Total Liabilities over the past 5 years was $16.1 million (2025), compared with a mean of $28.5 million.
  • Biggest five-year swings in Total Liabilities: skyrocketed 497.24% in 2021 and later crashed 84.08% in 2024.
  • Pulse Biosciences' Total Liabilities stood at $14.8 million in 2021, then surged by 441.6% to $80.1 million in 2022, then plummeted by 81.54% to $14.8 million in 2023, then increased by 18.95% to $17.6 million in 2024, then fell by 8.68% to $16.1 million in 2025.
  • The last three reported values for Total Liabilities were $16.1 million (Q3 2025), $15.8 million (Q2 2025), and $14.9 million (Q1 2025) per Business Quant data.